Kimia Biosciences Ltd. (KIMIABL): Kimia Biosciences Share Price Falls 8.68% Today; Micro Cap Pharma Stock in Focus

Kimia Biosciences Ltd. fell to Rs 26.1, down 8.68% today. The micro cap pharma company now has a market capitalisation of Rs 135.22 crore.

Kimia Biosciences Share Price fell to Rs 26.1 on 11 August 2026, down 8.68% from the previous close of Rs 28.58, placing the Healthcare stock among the notable market movers in today’s Stock Market Today action. With a market capitalisation of Rs 135.22 crore, Kimia Biosciences Ltd. sits in the Micro Cap category, making the magnitude of this single-session share price decline significant in category terms.

The day’s move was broad rather than narrow. The stock opened at Rs 28.99, touched an intraday high of Rs 29.13 and then fell to an intraday low of Rs 26.1, which was also the current price at the time captured by the supplied data. That sequence shows sustained selling pressure through the session instead of a brief dip that later recovered. On BSE, total traded volume stood at 19,264 shares, with turnover at Rs 0.05 crore.

For readers tracking Kimia Biosciences Share Price Today, the verified data confirms the price fall clearly, but it does not establish a company-specific catalyst behind the move. Even so, the stock is trending because the decline was large enough to clear the event bar for its own market-cap bucket. In this Univest analysis, the focus is on what the price action, valuation, profitability, sector benchmark and peer data say about Kimia Biosciences Share Price, and what investors may want to monitor next without treating the move as a recommendation.

Kimia Biosciences Ltd. (KIMIABL) Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 26.1
Previous Close	Rs 28.58
Today's Change	Rs -2.48 (-8.68%)
Day Open	Rs 28.99
Day High	Rs 29.13
Day Low	Rs 26.1
Current Volume (BSE)	19,264
BSE Traded Volume	19,264
Combined NSE + BSE Volume	19,264
Turnover	Rs 0.05 crore
Market Capitalisation	Rs 135.22 crore
Market Cap Category	Micro Cap

Kimia Biosciences Ltd. (KIMIABL) traded at Rs 26.1. versus the previous close of Rs 28.58, a fall of 8.68%. The stock opened at Rs 28.99, reached Rs 29.13, touched Rs 26.1. Reported volume was 19,264.

Kimia Biosciences Ltd. (KIMIABL) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 135.22 crore
P/E Ratio	18.82x
P/B Ratio	7.63x
ROE	32.19%
ROCE	16.13%
EPS	Rs 1.52
Dividend Yield	0%

Kimia Biosciences Ltd. was valued at a P/E ratio of 18.82x, a P/B ratio of 7.63x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.

Profitability and capital efficiency were represented by ROE of 32.19% and ROCE of 16.13%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.

Per-share and shareholder-return metrics included EPS of Rs 1.52, dividend yield of 0%. Dividend yield is a current or historical ratio and does not guarantee future distributions.

Kimia Biosciences Fundamental Analysis shows a mixed but interesting setup. The company’s market capitalisation stands at Rs 135.22 crore, which confirms its micro cap status and also frames how investors may interpret volatility. The stock trades at a P/E ratio of 18.82 and a P/B ratio of 7.63. On valuation alone, those two numbers send different messages: earnings valuation looks moderate against many pharma names, while the price-to-book multiple is much richer relative to book-based benchmarks.

Profitability metrics are notable. Return on equity is 32.19%, while return on capital employed is 16.13%. ROE at 32.19% is strong in absolute terms and suggests the business has generated substantial returns on shareholder capital. ROCE at 16.13% is also positive and indicates the company is producing returns above a basic low-return profile, although it is materially lower than ROE. That gap can matter in interpretation because ROE and ROCE do not always tell the same story about how efficiently the business converts capital into returns.

EPS is Rs 1.52, which gives investors a direct earnings-per-share reference behind the current stock price. At the same time, dividend yield is 0, meaning the stock is not currently reflecting a historical cash payout relative to the market price. For readers following Kimia Biosciences Share Price and Kimia Biosciences Earnings, that matters because the investment case in the supplied data leans more on profitability and valuation than on yield.

The combination of a P/E ratio of 18.82, P/B ratio of 7.63, ROE of 32.19% and ROCE of 16.13% suggests the market is assigning a meaningful value to the company’s equity base, while its profitability metrics remain stronger than many would assume from a stock that has just seen a sharp share price fall. In Univest’s reading, the supplied fundamentals do add context to investor attention, but they do not cancel out the significance of the day’s price decline. That makes sector and peer comparison essential before drawing broader conclusions from Kimia Biosciences Share Price News.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	18.82x
Benchmark Median P/E	25.7x
Benchmark Average P/E	69.27x
Benchmark P/E Range	3.08x to 3,396.3x
Company P/B Ratio	7.63x
Benchmark Median P/B	1.8x
Company ROE	32.19%
Benchmark Median ROE	10.59%
Company ROCE	16.13%
Benchmark Median ROCE	12.98%
Company Market Capitalisation	Rs 135.22 crore
Benchmark Median Market Cap	Rs 146.99 crore

Kimia Biosciences Ltd. (KIMIABL) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.

Kimia Biosciences Ltd. (KIMIABL) has a P/E ratio of 18.82x, which is below the benchmark median of 25.7x, a difference of -26.77%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Kimia Biosciences Ltd. (KIMIABL) has a ROE of 32.19%, which is above the benchmark median of 10.59%, a difference of +203.97%. Kimia Biosciences Ltd. (KIMIABL) has a ROCE of 16.13%, which is above the benchmark median of 12.98%, a difference of +24.27%.

Track today's top decliners through the Univest top decliners screener. The peer table below provides the company-level comparison.

Kimia Biosciences operates in the Healthcare sector and the Pharmaceuticals & Drugs industry, and the sector benchmark supplied here covers the same industry across 137 companies. That context is useful because it shows where the company sits on valuation, profitability and size relative to a broad listed set rather than in isolation.

On P/E, Kimia Biosciences stands at 18.82. Within the same-industry benchmark, the median P/E is 25.7 and the average is 69.27 across 104 companies, with a range from 3.08 to 3396.3. That places the company below both the benchmark median and average on earnings valuation. On this metric alone, Kimia Biosciences Share Price does not appear stretched versus the industry distribution provided. However, the P/B ratio tells a different story. The company’s P/B is 7.63, above the industry median of 1.8 and above the average of 2.49 across 136 companies, though still below the maximum of 15.98.

Profitability stands out more positively. ROE is 32.19%, far above the same-industry median of 10.59 and average of 8.24. ROCE is 16.13%, above the industry median of 12.98 and slightly above the average of 15.72. In other words, the company is trading with stronger-than-benchmark profitability, even as the market is pricing its book value at a clear premium to typical sector levels.

Size is also relevant. Kimia Biosciences has a market capitalisation of Rs 135.22 crore, below the benchmark median of Rs 146.99 crore and well below the benchmark average of Rs 500.01 crore. The industry range runs from Rs 6.55 crore to Rs 3,032.97 crore, so the company sits in the lower part of the size spectrum. For readers of Kimia Biosciences Share Price Update, the sector picture is therefore nuanced: lower-than-median P/E, above-median P/B, above-benchmark ROE and ROCE, and a market cap that remains smaller than the industry median.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Dishman Carbogen Amcis Ltd.	DCAL	3,032.97	0	0.76	-2.89	-0.26
Hikal Ltd.	HIKAL	2,799.54	0	2.32	15.22	16.15
Kwality Pharmaceuticals Ltd.	KPL	2,707.2	40.09	9.77	28.21	26.35
Beta Drugs Ltd.	BETA	2,631.45	66.92	10.59	18.65	22.17
Panacea Biotec Ltd.	PANACEABIO	2,531.49	0	8.67	0	5.36

Kimia Biosciences Ltd. (KIMIABL) has a P/E ratio of 18.82x compared with the displayed peer median of 0x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 32.19% compares with a peer median of 15.22% across the companies shown in the table. ROCE stood at 16.13% versus the displayed peer median of 16.15%, providing a capital-efficiency comparison. Kimia Biosciences Ltd. (KIMIABL) has a market capitalisation of Rs 135.22 crore. Among the 5 peers shown, 5 have a larger market capitalisation.

Kimia Biosciences Share Price also needs to be viewed against named peers from the Pharmaceuticals & Drugs space. Compared with larger listed players such as Hikal Ltd. at Rs 2,799.54 crore and Dishman Carbogen Amcis Ltd. at Rs 3,032.97 crore in market capitalisation, Kimia Biosciences remains much smaller at Rs 135.22 crore. That market-cap gap alone means direct one-to-one comparisons should be made carefully, but the peer figures still offer useful perspective on valuation and operating quality.

On P/E, Kimia Biosciences at 18.82 sits below Kwality Pharmaceuticals at 40.09, Beta Drugs at 66.92, NGL Fine-Chem at 44.48 and Sai Parenteral's at 181.97. It is slightly above Venus Remedies at 17.49 and above Hester Biosciences at 15.63. That places the stock in the lower end of the available peer P/E range among peers where P/E is supplied.

On profitability, Kimia Biosciences reports ROE of 32.19%, which is higher than Hikal’s 15.22%, Kwality Pharmaceuticals’ 28.21%, Beta Drugs’ 18.65%, Panacea Biotec’s 0, Sai Parenteral's 13.9%, Solara’s 17.23%, NGL Fine-Chem’s 27.9%, Venus Remedies’ 9.85% and Hester Biosciences’ 16.17%. That is one of the strongest ROE readings in the supplied comparison set.

ROCE at 16.13% is more middle-of-the-pack. It is close to Hikal’s 16.15% and above peers such as Panacea Biotec at 5.36%, Venus Remedies at 7.89%, Hester Biosciences at 14.12% and Solara at 15.34%. However, it trails Kwality Pharmaceuticals at 26.35%, Beta Drugs at 22.17% and NGL Fine-Chem at 33.91%.

The P/B ratio of 7.63 is also on the richer side versus Hikal at 2.32, Solara at 1.93, Hester Biosciences at 4.68 and Venus Remedies at 2.96, though below Kwality Pharmaceuticals at 9.77, Beta Drugs at 10.59 and Panacea Biotec at 8.67. The peer picture from Univest therefore suggests that Kimia Biosciences combines relatively modest earnings valuation with premium book valuation and strong ROE, while its ROCE is respectable rather than best-in-class.

Why Investors Are Watching Kimia Biosciences

Kimia Biosciences Share Price is in focus because a sharp single-session move in a micro cap stock can quickly shift attention toward liquidity, valuation and comparative profitability. The stock’s decline of 8.68%, the fact that it finished at the day’s low of Rs 26.1, and its distinct position within the listed Pharmaceuticals & Drugs space make it relevant in today’s market news flow.

• Price action: The stock fell Rs 2.48 from Rs 28.58 to Rs 26.1 after opening at Rs 28.99 and touching Rs 29.13.
• Intraday tone: Current price at the day low indicates pressure persisted through the recorded session.
• Liquidity snapshot: BSE volume was 19,264 shares with turnover of Rs 0.05 crore.
• Fundamental context: P/E is 18.82, P/B is 7.63, ROE is 32.19% and ROCE is 16.13%.
• Sector positioning: P/E is below industry median, while P/B is above industry median and profitability is ahead of benchmark levels.
• Peer standing: ROE compares strongly with the supplied peer set, while ROCE is more moderate.

What investors may monitor next is whether Kimia Biosciences Share Price stabilises away from the day low, how valuation is interpreted after the share price decline, and whether future Kimia Biosciences Company News or Kimia Biosciences Financial Results alter the balance between premium book valuation and strong profitability metrics. Univest sees this as a stock worth tracking for data changes rather than assumptions.

About Kimia Biosciences

Kimia Biosciences Ltd. is part of the Healthcare sector and operates within the Pharmaceuticals & Drugs industry. Based on the supplied company context, the stock should be understood primarily through its industry positioning rather than through a broad conglomerate lens. That places it in a segment of the Indian Stock Market where investors usually pay close attention to earnings multiples, return ratios and relative scale against other listed drug and healthcare businesses.

Within the benchmark set provided, the company sits in an industry featuring 137 listed peers with market capitalisations ranging from Rs 6.55 crore to Rs 3,032.97 crore. Kimia Biosciences, at Rs 135.22 crore, is smaller than many of the better-known listed names in the same industry and is categorised as a micro cap stock. That size profile often means Kimia Biosciences Share Price can attract attention during sharp sessions because even modest turnover can coincide with visible price movement.

Its supplied financial profile shows a business that, at least on reported ratios, delivers stronger profitability than a large part of the same-industry benchmark. ROE of 32.19% and ROCE of 16.13% stand out in that context. At the same time, the stock trades at a P/B ratio of 7.63, which is above the industry median, indicating that the market has historically placed a higher value on its equity base than on many sector counterparts. That mix is central to any serious Kimia Biosciences Stock Analysis.

Track Kimia Biosciences Share Price on Univest

Use Kimia Biosciences Ltd. (KIMIABL) live share-price page, Univest top decliners screener, Univest market blogs to review live stock data, top decliners lists and related market analysis.

Readers following Kimia Biosciences Share Price can use Univest to track live price moves, market capitalisation changes, valuation ratios and broader stock analysis in one place. For stocks such as Kimia Biosciences Ltd., which can enter the Top Losers Today screen on a sharp single-day move, having a single dashboard for price, peer comparison, sector metrics and shareholding pattern can improve context around the numbers.

Univest also helps users monitor Kimia Biosciences Share Price Today alongside key data points such as 52-week levels, profitability ratios, market-cap classification and market insights. For investors comparing BSE-listed healthcare names, that makes it easier to place Kimia Biosciences Share News within the wider Pharmaceuticals & Drugs universe without relying on isolated price action alone.

Frequently Asked Questions

Why is Kimia Biosciences Share Price falling today?

Ans. Kimia Biosciences Share Price fell 8.68% to Rs 26.1 from the previous close of Rs 28.58. The supplied data confirms the price fall and intraday weakness, but it does not establish any company-specific reason for the decline.

What is Kimia Biosciences Share Price Today?

Ans. Kimia Biosciences Share Price Today is Rs 26.1. The stock was down Rs 2.48, or 8.68%, versus the previous close of Rs 28.58, and the recorded current price was also the intraday low for the session.

How did Kimia Biosciences stock trade during the session?

Ans. The stock opened at Rs 28.99, rose to Rs 29.13 and later declined to Rs 26.1. That means the session moved from an early higher level into a deeper price fall by the latest recorded trade.

What is the market capitalisation of Kimia Biosciences Ltd.?

Ans. Kimia Biosciences Ltd. has a market capitalisation of Rs 135.22 crore. That places it in the Micro Cap category, which is important because the day’s 8.68% decline was significant within its own market-cap bucket.

Is Kimia Biosciences expensive or cheap on P/E?

Ans. On the supplied data, Kimia Biosciences trades at a P/E of 18.82. That is below the same-industry median of 25.7 and below the average of 69.27, suggesting a lower earnings multiple than the benchmark set.

How does Kimia Biosciences compare on P/B ratio?

Ans. Kimia Biosciences has a P/B ratio of 7.63. This is above the same-industry median of 1.8 and above the average of 2.49, indicating a richer book-value valuation than many companies in the benchmark.

What do the profitability ratios of Kimia Biosciences show?

Ans. The company reports ROE of 32.19% and ROCE of 16.13%. ROE is well above the industry median of 10.59, while ROCE is above the median of 12.98 and slightly above the average of 15.72.

What are the EPS and dividend yield of Kimia Biosciences?

Ans. Kimia Biosciences reports EPS of Rs 1.52 and a dividend yield of 0. The supplied figures show earnings per share are positive, while the stock currently does not reflect a historical payout yield at market price.

What was the trading volume in Kimia Biosciences today?

Ans. Total traded volume was 19,264 shares, reported on BSE, and turnover stood at Rs 0.05 crore. These figures confirm that the day’s share price decline occurred with actual exchange participation, not a purely notional move.

How does Kimia Biosciences compare with pharma peers?

Ans. Kimia Biosciences has stronger ROE than several supplied peers, including Hikal, Solara and Hester Biosciences. Its P/E of 18.82 is below peers such as Kwality Pharmaceuticals, Beta Drugs and NGL Fine-Chem, while its market cap is much smaller.